Evidence map›Paper›PMID 39719526›Full record

ArticleEndocrine2025

Primary hyperparathyroidism in patients with thyroid cancer: prevalence and prognosis in a retrospective monocentric study.

I Patelli, M Comina, L Musso, A De'Luca Di Pietralata, L Vera, M Minuto, M Albertelli, M Giusti, M Bagnasco, D Ferone and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

I PatelliEndocrine Unit, Department of Internal Medicine & Medical Specialties, University of Genova, Genova, Italy.
M CominaEndocrine and Metabolism Center, ASL1, Imperia, Italy.
L MussoEndocrine Unit, Department of Internal Medicine & Medical Specialties, University of Genova, Genova, Italy.
A De'Luca Di PietralataEndocrine Unit, Department of Internal Medicine & Medical Specialties, University of Genova, Genova, Italy.
L VeraEndocrine Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
M MinutoEndocrine Surgery Unit, Department of Surgery, IRCCS Polyclinic Hospital San Martino and Department of Surgical Sciences (DISC), University of Genoa, Genova, Italy.
M AlbertelliEndocrine Unit, Department of Internal Medicine & Medical Specialties, University of Genova, Genova, Italy.
M GiustiEndocrine Unit, Department of Internal Medicine & Medical Specialties, University of Genova, Genova, Italy.
M BagnascoInternal Medicine Unit, Department of Internal Medicine & Medical Specialties, University of Genova, Genova, Italy.
D FeroneEndocrine Unit, Department of Internal Medicine & Medical Specialties, University of Genova, Genova, Italy.
S GayEndocrine Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy. stefano.gay@hsanmartino.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePrimary hyperparathyroidism (PHPT) is associated with long-term implications on many aspects of general health and has been linked to various tumor types. This retrospective monocentric study aimed to evaluate the prevalence of primary hyperparathyroidism in a cohort of thyroid cancer patients and its impact on their general prognosis.

methodsThe prevalence of primary hyperparathyroidism (concomitant or subsequent) was retrospectively evaluated in a cohort of 450 patients with a diagnosis of differentiated thyroid cancer. Its association with oncological outcomes and overall survival was analysed.

resultsAmong the study population, 30 patients (6,7%) were diagnosed with primary hyperparathyroidism. This subgroup displayed older age at diagnosis and a higher prevalence of prior cardiovascular disease, other primary tumors and multinodular goiter (p < 0.001). PHPT was associated with increased mortality; however, no significant difference in thyroid cancer-specific mortality was found.

conclusionA significant proportion of thyroid cancer patients may present concomitant primary hyperparathyroidism, which appears to negatively affect long-term prognosis, independently from their oncological outcomes.

Indexed as

Hyperparathyroidism, PrimaryThyroid NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrevalencePrognosisRetrospective StudiesDifferentiated thyroid cancerParathyroidPrimary hyperparathyroidismThyroidThyroid cancer

Identifiers

PMID39719526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.